URGENT UPDATE: Shares of FTSE 100 medical technology group Smith & Nephew (LSE: SN) have plunged 14% from their one-year high of £14.41 reached on September 10. This drastic drop comes despite the company reporting its most impressive operational performance in a decade for the full year of 2025.
On March 2, Smith & Nephew announced its full-year results, which highlighted significant progress following the completion of its ambitious 12-Point Plan. This initiative effectively resolved supply issues, streamlined its product portfolio, and revitalized growth in its crucial Orthopaedics division. The current share price of £12.46 raises questions about potential undervaluation in the wake of such strong business fundamentals.
Analysts predict robust earnings growth of 12.5% annually through to the end of 2028. The business’s recent performance backs this forecast, with trading profit surging 15.5% to $1.2 billion (£0.9 billion), raising the trading margin by 160 basis points to 19.7%—the highest profitability level the company has delivered in a decade. Revenue also increased by 6.1% to $6.16 billion, aided by easing supply constraints and enhanced operational execution.
The company saw free cash flow soar by 52.5% to $840 million, reflecting both improved earnings and disciplined working capital management. Additionally, the return on invested capital strengthened to 8.3%, despite challenges from portfolio rationalization.
Positive momentum across its divisions is evident, particularly in Orthopaedics, which has returned to growth driven by improved logistics and heightened surgeon engagement, alongside increased adoption of the CORI robotics platform. The Sports Medicine & ENT division also reported double-digit growth, propelled by strong demand for joint repair products and innovative implants.
Management projects a return on invested capital of 12%-13% and forecasts a 9%-10% compound annual growth rate in trading profit through 2028. These indicators suggest a company on the path to sustained value creation and rising efficiency.
To assess Smith & Nephew’s true value, a discounted cash flow (DCF) analysis was conducted, estimating the shares are currently 28% undervalued based on a price of £12.46. This valuation implies a fair value of approximately £17.31, significantly higher than its current trading price, suggesting an enticing buying opportunity for investors.
As a seasoned investor, I typically gravitate towards high-yield stocks, though Smith & Nephew currently offers a yield of only 2.3%. However, this company could be ideal for those seeking growth through improving profitability and a credible multi-year turnaround that is already evident in its results.
Investors are urged to monitor Smith & Nephew closely as the market reacts to these developments. The potential for recovery in share price, alongside the company’s promising growth prospects, raises critical questions about the best strategies for investment in this leading med-tech firm.
For those considering investing £1,000 in Smith & Nephew, expert Mark Rogers emphasizes the importance of informed decision-making. His insights currently spotlight six standout stocks that merit attention, including Smith & Nephew.
Stay tuned for further updates on this developing story as market dynamics evolve.
